Silence Therapeutics PLC Sponsored ADR

SLN Healthcare Biotechnology

Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024. In the quarter to June 2026, revenue grew 197.2%, EPS grew 54.4% and free cash flow grew 107.0%, each against the same quarter a year earlier.

8.68 0.67 −7.17%
Market cap
$581.1M
P/E
0.0×
Fwd P/E
−7.6×
Dividend yield
—
F-score
2/9
Altman Z
−4.82
Beneish M
45.78
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — — — — 3 5 5 2
P/E ratio
0.00 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
— — — — 0.04 (0.27) (1.14) (1.80) (0.30) (4.82)
P/S ratio
0.00 0.00 — 0.00 0.00 20.33 21.85 21.74 7.36 513.72
Altman Z″-Score (non-manufacturers)
31.74 — — — (5.79) (5.80) (6.19) (10.73) (2.15) (12.42)
P/FCF ratio
0.00 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
— — — — — (4.17) (1.55) (2.39) (1.86) 45.78
P/Operating CF
374.87 374.87 — 374.87 (44.15) (52.53) (25.59) (46.90) (11.58) (16.61)
P/B ratio
12.43 12.43 — 12.43 52.52 45.82 17.32 31.29 2.37 4.61
Price to Tangible BV
17.74 17.74 — 17.74 518.60 429.28 27.82 59.06 2.56 5.59
EV/Sales
0.00 0.00 — 0.00 0.00 16.50 17.78 19.57 3.95 361.63
EV/EBITDA
0.00 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(291.34) (291.34) — (291.34) (108.15) (36.56) (6.85) (12.52) (2.53) (3.25)
EV/FCF
(291.34) (291.34) — (291.34) (108.15) (36.56) (6.83) (12.51) (2.52) (3.24)
Quick Ratio
25.92 16.95 7.57 3.84 2.81 5.33 3.96 4.10 10.27 7.87
Current Ratio
26.09 17.14 7.70 3.88 2.99 5.69 4.41 4.62 11.14 8.72
Net Debt/EBITDA
3.36 3.24 1.26 1.56 1.10 1.62 1.48 1.08 2.35 0.94
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.01 0.00 0.00 0.01 0.08 0.14 0.16 0.25 0.27 0.00
Operating CF/Net income
1.17 5.94 0.91 (0.09) 0.33 (0.17) 1.12 0.91 1.49 0.70
Capex/Depreciation
0.00 0.00 0.00 0.00 (1.03) (3.12) (0.91) (0.09) (0.36) (0.10)
Interest Coverage
(15.42) (1,920.53) (1,054.67) (1,686.05) (110.99) (881.10) (1,034.50) (24.05) — —
ROE
(15.14%) (3.46%) (41.16%) (70.17%) (173.84%) (464.06%) (256.66%) (220.02%) (58.08%) (90.27%)
ROA
(14.55%) (8.18%) (47.55%) (103.54%) (48.07%) (44.66%) (37.76%) (42.97%) (28.13%) (53.05%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(20.20%) (3.50%) (72.49%) (66.35%) (62.65%) (53.91%) (52.62%) (65.53%) (26.29%) (83.11%)
Average Days of Receivables
1,285.08 47,122.21 0.00 5,465.97 2,187.88 213.91 329.46 262.21 214.05 14,369.51
Research and Development Expense of Revenue
1,130.26% 49,537.38% 0.00% 5,452.94% 368.85% 247.80% 203.45% 179.94% 156.93% 12,120.39%
Selling, General and Administrative Expense of Revenue
475.71% 29,368.93% 0.00% 3,765.34% 255.21% 161.16% 112.05% 82.87% 62.15% 3,997.14%
Intangible Assets out of Total Assets
0.14 0.00 0.21 0.00 0.09 0.08 0.08 0.09 0.05 0.08
Share Based Compensation of Revenue
0.00% 0.00% — 0.00% 80.22% 69.53% 58.58% 51.43% 37.70% 1,444.36%
Graham Net Nets
0.05 0.05 — 0.05 0.00 0.00 0.03 0.01 0.37 0.17
Graham Number
0.00 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(8.70%) (8.70%) — (8.70%) (13.19%) (18.22%) (10.62%) (7.87%) (13.81%) (30.76%)
Free Cash Flow Yield
(0.29%) (0.29%) — (0.29%) (0.85%) (2.22%) (11.92%) (7.20%) (21.32%) (21.70%)
Revenue per Share
0.04 0.00 0.00 0.02 0.26 0.58 0.67 0.85 0.94 0.01
Operating CF per Share
(0.52) (0.59) (1.22) 0.11 (0.51) 0.32 (1.75) (1.33) (1.46) (1.32)
Capex per Share
0.00 0.00 0.00 0.00 (0.02) (0.06) (0.02) 0.00 0.00 0.00
Free Cash Flow per Share
(0.52) (0.59) (1.22) 0.11 (0.53) 0.25 (1.76) (1.33) (1.47) (1.32)
Cash per Share
2.03 2.79 1.85 2.33 1.83 3.41 2.73 1.85 3.19 1.80
Shareholders Equity per Share
2.82 3.39 2.44 1.46 0.43 0.40 0.85 0.59 2.90 1.32
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
2.82 3.39 2.44 1.46 0.43 0.40 0.85 0.59 2.90 1.32
Free Cash Flow
(12.23) (16.73) (28.58) 2.82 (14.49) 7.52 (56.77) (49.52) (67.85) (62.33)
Working Capital
49.88 78.40 41.91 48.48 65.26 97.86 92.45 80.82 170.54 105.05
Capital Expenditures
(0.66) (0.30) (0.32) (0.02) (0.66) (1.83) (0.54) (0.06) (0.21) (0.05)
Net Current Asset Value
49.88 78.40 41.91 21.43 (0.66) (1.84) 13.93 5.70 118.75 49.52
EV/EBIT
0.00 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 — 0.00 0.09 0.11 0.03 0.00 0.00 0.10
Price to Operating Income
0.00 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.23 0.35 0.45 0.76 0.44 0.22 0.22 0.32 0.33 0.35
Cash ROIC
(10.63%) (9.59%) (28.42%) 2.97% (23.51%) 6.67% (49.24%) (54.55%) (24.12%) (42.28%)
Accounts Receivable Turnover
0.32 0.01 0.00 0.08 0.29 0.65 1.47 1.50 1.80 0.02
Accounts Payable Turnover
0.60 1.01 0.50 0.00 0.71 0.81 0.88 0.83 0.74 0.01
Inventory Turnover
0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
621.68 409.12 1,002.24 0.00 794.81 527.87 423.81 440.74 506.83 22,674.14
Days of Inventory on Hand
0.00 0.00 0.00 — 0.00 0.00 0.00 0.00 0.00 0.00
Average Receivables
3.00 3.47 3.79 5.06 24.15 26.09 14.77 21.14 24.05 23.69
Average Payables
0.64 0.75 1.36 2.50 6.82 12.67 15.23 15.58 15.97 14.88
Average Assets
71.61 34.44 66.19 31.75 86.94 121.33 132.62 126.21 161.04 167.04
Average Common Equity
68.82 81.30 76.47 46.84 24.04 11.68 19.51 24.65 78.01 98.16

Fold the line items

Columns are period end dates